These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23171332)

  • 1. Pharmacogenetics in solid organ transplantation: a transition from kinetics to dynamics.
    Kuypers DR
    Pharmacogenomics; 2012 Nov; 13(15):1679-83. PubMed ID: 23171332
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients.
    Woillard JB; Kamar N; Rousseau A; Rostaing L; Marquet P; Picard N
    Pharmacogenet Genomics; 2012 Oct; 22(10):725-32. PubMed ID: 22863900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F; Andrés A; Oppenheimer F
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunosuppressive agents in kidney transplantation].
    Nishi S
    Nihon Jinzo Gakkai Shi; 2011; 53(1):1-5. PubMed ID: 21370569
    [No Abstract]   [Full Text] [Related]  

  • 5. Sirolimus to replace calcineurin inhibitors? Too early yet.
    Cravedi P; Ruggenenti P; Remuzzi G
    Lancet; 2009 Apr; 373(9671):1235-6. PubMed ID: 19362662
    [No Abstract]   [Full Text] [Related]  

  • 6. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins.
    Stallone G; Infante B; Pontrelli P; Gigante M; Montemurno E; Loverre A; Rossini M; Schena FP; Grandaliano G; Gesualdo L
    Transplantation; 2011 May; 91(9):997-1004. PubMed ID: 21364499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy.
    Hartmann B; Schmid G; Graeb C; Bruns CJ; Fischereder M; Jauch KW; Heeschen C; Guba M
    Kidney Int; 2005 Dec; 68(6):2593-8. PubMed ID: 16316335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pros and the cons of mTOR inhibitors in kidney transplantation.
    Ponticelli C
    Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus-induced lymphoedema.
    Motse KG; Mashabane MJ
    S Afr Med J; 2016 Aug; 106(9):886-7. PubMed ID: 27601112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus rescue of renal failure in children after combined liver-kidney transplantation.
    Vester U; Kranz B; Nadalin S; Paul A; Becker J; Hoyer PF
    Pediatr Nephrol; 2005 May; 20(5):686-9. PubMed ID: 15723197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-gamma and intimal hyperplasia.
    Rose ML
    Circ Res; 2007 Sep; 101(6):542-4. PubMed ID: 17872472
    [No Abstract]   [Full Text] [Related]  

  • 12. Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome.
    Shah S; Harwood SM; Döhler B; Opelz G; Yaqoob MM
    Transplantation; 2012 Sep; 94(5):486-91. PubMed ID: 22960765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus: efficacy and safety in cardiac transplantation.
    Schaffer SA; Ross HJ
    Expert Opin Drug Saf; 2010 Sep; 9(5):843-54. PubMed ID: 20701555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus, the first mTOR inhibitor.
    Sánchez-Plumed JA; González Molina M; Alonso A; Arias M
    Nefrologia; 2006; 26 Suppl 2():21-32. PubMed ID: 17937632
    [No Abstract]   [Full Text] [Related]  

  • 15. Sirolimus for solid organ transplantation in children.
    Gupta P; Kaufman S; Fishbein TM
    Pediatr Transplant; 2005 Jun; 9(3):269-76. PubMed ID: 15910380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genes and beans: pharmacogenomics of renal transplant.
    Murray B; Hawes E; Lee RA; Watson R; Roederer MW
    Pharmacogenomics; 2013 May; 14(7):783-98. PubMed ID: 23651025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological action of rapamycin in renal transplantation.
    Weichhart T; Werzowa J; Hörl WH; Säemann MD
    Am J Kidney Dis; 2008 Mar; 51(3):531; author reply 531-2. PubMed ID: 18295073
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation.
    Geissler EK; Schlitt HJ
    Kidney Int; 2010 Dec; 78(11):1075-9. PubMed ID: 20861822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR Inhibition and Clinical Transplantation: Kidney.
    Flechner SM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.